Biomea Fusion【BMEA】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

4.08

買値

4.00

売値

4.39

出来高

0.00 日の範囲 0.00

3.65 52 週間の範囲 20.21

時価総額

147.854M

前日終値

4.08

始値

時刻

4.08

最終取引時間

19:55:25

財務取引量

VWAP

平均取引量 (3 か月)

849,169

発行済株式数

36,238,687

配当利回り

PER

-1.26

1 株当たり利益 (EPS)

-3.24

歳入

純利益

-117.26M

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.biomeafusion.com

本社

Wilmington, Delaware, USA

設立

Biomea Fusion Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker BMEA. The last closing price for Biomea Fusion was US$4.08. Over the last year, Biomea Fusion shares have traded in a share price range of US$ 3.65 to US$ 20.21.

Biomea Fusion currently has 36,238,687 shares in issue. The market capitalisation of Biomea Fusion is US$147.85 million. Biomea Fusion has a price to earnings ratio (PE ratio) of -1.26.

全体の流れ

ベアリッシュ

ネットプレミアム

-211k

Calls / Puts

0.00%

買い / 売り

20.00%

OTM / ITM

0.00%

Sweeps比率

0.00%

Form 8-K - Current report

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response...

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression...

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and...

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type 2 Diabetes Patients Characterized by Insulin Deficiency 32 patients from the 100mg and...

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.02	-0.487804878049	4.1	4.29	3.89	590847	4.10804391	CS
4	-3.1	-43.1754874652	7.18	7.46	3.81	1080069	5.0006792	CS
12	-6.12	-60	10.2	13.07	3.81	849169	7.57161127	CS
26	-0.42	-9.33333333333	4.5	13.07	3.81	811571	7.21133549	CS
52	-11.29	-73.4547820429	15.37	20.21	3.65	994765	9.86231695	CS
156	-3.72	-47.6923076923	7.8	43.69	2.84	639417	14.6888191	CS
260	-15.92	-79.6	20	43.69	2.84	544465	14.63307642	CS

BMEA - Frequently Asked Questions (FAQ)

What is the current Biomea Fusion share price?

The current share price of Biomea Fusion is US$ 4.08

How many Biomea Fusion shares are in issue?

Biomea Fusion has 36,238,687 shares in issue

What is the market cap of Biomea Fusion?

The market capitalisation of Biomea Fusion is USD 147.85M

What is the 1 year trading range for Biomea Fusion share price?

Biomea Fusion has traded in the range of US$ 3.65 to US$ 20.21 during the past year

What is the PE ratio of Biomea Fusion?

The price to earnings ratio of Biomea Fusion is -1.26

What is the reporting currency for Biomea Fusion?

Biomea Fusion reports financial results in USD

What is the latest annual profit for Biomea Fusion?

The latest annual profit of Biomea Fusion is USD -117.26M

What is the registered address of Biomea Fusion?

The registered address for Biomea Fusion is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Biomea Fusion website address?

The website address for Biomea Fusion is www.biomeafusion.com

Which industry sector does Biomea Fusion operate in?

Biomea Fusion operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
INTZIntrusion Inc	US$ 2.53 (462.22%)	35.84M
RVSNRail Vision Ltd	US$ 1.41 (82.26%)	9.85M
SLDPSolid Power Inc	US$ 3.27 (67.69%)	7.72M
IDAIT Stamp Inc	US$ 0.902 (67.04%)	14.51M
EVAXEvaxion Biotech AS	US$ 1.37 (61.94%)	1.76M
LATGChenghe Acquisition I Company	US$ 9.50 (-23.23%)	167
KALVKalVista Pharmaceuticals Inc	US$ 7.01 (-20.61%)	1
QRHCQuest Resource Holding Corporation	US$ 5.00 (-19.35%)	419
LRFCLogan Ridge Finance Corporation	US$ 20.00 (-19.26%)	204
GOCOGoHealth Inc	US$ 11.01 (-17.71%)	7
INTZIntrusion Inc	US$ 2.53 (462.22%)	35.84M
IDAIT Stamp Inc	US$ 0.902 (67.04%)	14.51M
RVSNRail Vision Ltd	US$ 1.41 (82.26%)	9.85M
QSIQuantum Si Inc	US$ 2.87 (33.49%)	9.73M
SLDPSolid Power Inc	US$ 3.27 (67.69%)	7.72M